このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Cryoport 将来の成長

Future 基準チェック /16

Cryoport利益と収益がそれぞれ年間34.5%と9.6%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-11.8% 36.6%なると予測されています。

主要情報

35.1%

収益成長率

36.6%

EPS成長率

Life Sciences 収益成長	16.8%
収益成長率	9.6%
将来の株主資本利益率	-11.8%
アナリストカバレッジ	Good
最終更新日	21 Jun 2024

今後の成長に関する最新情報

Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 15

Recent updates

Potential Upside For Cryoport, Inc. (NASDAQ:CYRX) Not Without Risk

Apr 15

Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 15

Downgrade: Here's How Analysts See Cryoport, Inc. (NASDAQ:CYRX) Performing In The Near Term

Jul 23

Cryoport, Inc.'s (NASDAQ:CYRX) Subdued P/S Might Signal An Opportunity

Jul 12

Is Cryoport (NASDAQ:CYRX) A Risky Investment?

Jun 13

Cryoport, Inc.'s (NASDAQ:CYRX) Intrinsic Value Is Potentially 96% Above Its Share Price

Mar 06

Cryoport, Inc. (NASDAQ:CYRX) Analysts Just Cut Their EPS Forecasts Substantially

Nov 07

Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?

Sep 23

Cryoport: A Rare Investing Opportunity

Sep 22

Cryoport enters into strategic relationship with Takeda's BioLife Plasma Services

Sep 08

Cryoport: Rapid Growth Is Great, But Shares Look Overpriced

Jul 30

Cryoport: To Resume Aggressive Growth

May 11

Cryoport: An Industry Leader Basking In Industry Tailwinds

Apr 15

Cryoport: Risky Investment With Upside Potential

Apr 01

Cryoport: More Growth Going Into New Year 2022

Dec 29

Is Cryoport, Inc. (NASDAQ:CYRX) Trading At A 49% Discount?

Dec 05

What Is Cryoport, Inc.'s (NASDAQ:CYRX) Share Price Doing?

Nov 09

Is Cryoport (NASDAQ:CYRX) Using Too Much Debt?

Oct 17

Cryoport: The Golden Stock

Oct 08

Cryoport: Unfairly Punished, Valuation Update Shows 45% Upside

Oct 01

Cryoport: Best Price-Positioned Medical Services Stock, As Seen By Market-Makers

Jul 01

業績と収益の成長予測

NasdaqCM:CYRX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	295	-55	13	26	5
12/31/2025	266	-55	-12	5	9
12/31/2024	242	-69	-45	-22	10
3/31/2024	225	-121	-46	-7	N/A
12/31/2023	233	-108	-46	-1	N/A
9/30/2023	236	-55	-41	0	N/A
6/30/2023	241	-47	-32	3	N/A
3/31/2023	248	-38	-29	0	N/A
12/31/2022	237	-45	-26	-2	N/A
9/30/2022	233	-296	-27	-3	N/A
6/30/2022	230	-297	-23	5	N/A
3/31/2022	222	-293	-12	15	N/A
12/31/2021	223	-284	-17	8	N/A
9/30/2021	215	-76	-25	-4	N/A
6/30/2021	169	-78	-32	-18	N/A
3/31/2021	122	-77	-34	-22	N/A
12/31/2020	79	-75	-25	-15	N/A
9/30/2020	40	-22	-11	-4	N/A
6/30/2020	38	-23	-6	0	N/A
3/31/2020	37	-20	-5	0	N/A
12/31/2019	34	-18	-7	-1	N/A
9/30/2019	30	-20	-8	-2	N/A
6/30/2019	26	-9	-7	-2	N/A
3/31/2019	22	-9	-6	-2	N/A
12/31/2018	20	-10	-6	-3	N/A
9/30/2018	17	-10	-7	-4	N/A
6/30/2018	15	-9	-6	-5	N/A
3/31/2018	13	-9	-5	-4	N/A
12/31/2017	12	-8	N/A	-4	N/A
9/30/2017	11	-10	N/A	-3	N/A
6/30/2017	10	-10	N/A	-4	N/A
3/31/2017	9	-12	N/A	-5	N/A
12/31/2016	8	-13	N/A	-6	N/A
9/30/2016	7	-12	N/A	-6	N/A
6/30/2016	6	-12	N/A	-6	N/A
3/31/2016	6	-15	N/A	-6	N/A
12/31/2015	6	-16	N/A	-6	N/A
9/30/2015	5	-15	N/A	-5	N/A
6/30/2015	4	-16	N/A	-5	N/A
3/31/2015	4	-12	N/A	-4	N/A
12/31/2014	4	-10	N/A	-4	N/A
9/30/2014	3	-10	N/A	-4	N/A
6/30/2014	3	-21	N/A	-4	N/A
3/31/2014	3	-20	N/A	-4	N/A
12/31/2013	2	-20	N/A	-4	N/A
9/30/2013	2	-20	N/A	-4	N/A
6/30/2013	1	-6	N/A	-5	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CYRX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CYRX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CYRX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CYRXの収益 ( 9.6% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: CYRXの収益 ( 9.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CYRX 3 年以内に赤字になると予測されています。

Cryoport 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 14%

Cryoport, Inc. Reiterates Revenue Guidance for the Full Year 2024

Consensus EPS estimates fall by 26%

Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Cryoport, Inc. Provides Revenue Guidance for the Year 2023

Consensus EPS estimates fall by 35%

Recent updates

Independent Lead Director recently sold US$109k worth of stock

Consensus EPS estimates fall by 14%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Cryoport, Inc. Reiterates Revenue Guidance for the Full Year 2024

Cryoport, Inc. to Report Q1, 2024 Results on May 07, 2024

Potential Upside For Cryoport, Inc. (NASDAQ:CYRX) Not Without Risk

Cryoport, Inc., Annual General Meeting, May 17, 2024

Insufficient new directors

Consensus EPS estimates fall by 26%

Chairman notifies of intention to sell stock

Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Cryoport Tanks On Chilling Results And Bad Decisions

Cryoport, Inc. Announces Goodwill Impairment for the Quarter Ended December 31, 2023

Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?

Cryoport, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Cryoport, Inc. Announces Transition of Edward Zecchini from the Board of Directors to Sr. Vice President - Chief Digital & Technology Officer

Fewer Investors Than Expected Jumping On Cryoport, Inc. (NASDAQ:CYRX)

Cryoport, Inc. (NasdaqCM:CYRX) acquired Bluebird Express LLC.

New minor risk - Share price stability

Cryoport, Inc. Provides Revenue Guidance for the Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cryoport, Inc. (NasdaqCM:CYRX) acquired Tec4Med Lifescience GmbH.

Cryoport, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?

Chairman notifies of intention to sell stock

Consensus EPS estimates fall by 35%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS misses analyst expectations

Cryoport, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Downgrade: Here's How Analysts See Cryoport, Inc. (NASDAQ:CYRX) Performing In The Near Term

Consensus EPS estimates fall by 19%

Price target decreased by 17% to US$25.75

Cryoport, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2023

Cryoport, Inc.'s (NASDAQ:CYRX) Subdued P/S Might Signal An Opportunity

Is Cryoport (NASDAQ:CYRX) A Risky Investment?

Independent Lead Director recently sold US$155k worth of stock

Consensus EPS estimates upgraded to US$0.66 loss

First quarter 2023 earnings: EPS exceeds analyst expectations

Cryoport, Inc. Provides Revenue Guidance for the Year 2023

Chairman recently sold US$54k worth of stock

Cryoport, Inc.'s (NASDAQ:CYRX) Intrinsic Value Is Potentially 96% Above Its Share Price

Consensus EPS estimates fall by 54%, revenue upgraded

Full year 2022 earnings: EPS misses analyst expectations

No longer forecast to breakeven

Cryoport, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Forecast to breakeven in 2025

Independent Lead Director recently sold US$142k worth of stock

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 10%

Cryoport, Inc. (NASDAQ:CYRX) Analysts Just Cut Their EPS Forecasts Substantially

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$46.11

Cryoport, Inc. Revises Revenue Guidance for the Year 2022

Cryoport, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?

Cryoport: A Rare Investing Opportunity

Cryoport enters into strategic relationship with Takeda's BioLife Plasma Services

Independent Lead Director recently sold US$117k worth of stock

Consensus forecasts updated

No longer forecast to breakeven

Second quarter 2022 earnings: EPS misses analyst expectations

Cryoport, Inc. (NasdaqCM:CYRX) acquired Cell Matters Sa.

Cryoport: Rapid Growth Is Great, But Shares Look Overpriced

Cryoport, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Forecast to breakeven in 2024

Cryoport: To Resume Aggressive Growth

Cryoport, Inc. Provides Revenue Guidance for the Full Year 2022

Cryoport, Inc. (NasdaqCM:CYRX) acquired Cell&co for €6.2 million.

Cryoport: An Industry Leader Basking In Industry Tailwinds